BUSINESS Drugmaker Bristol-Myers Squibb says to buy Celgene in $74bn deal

BUSINESS

Drugmaker Bristol-Myers Squibb says to buy Celgene in $74bn deal

AFP

21:08, January 03, 2019

New York-based pharmaceutical giant Bristol-Myers Squibb announced Thursday it will buy biotech firm Celgene in a $74 billion cash and stock deal to create a specialized biopharma company.

VCG111159718387.jpg

Photos: VCG

The completed deal will see Bristol-Myers shareholders own about 69 percent of the merged company, with 31 percent going to Celgene shareholders, according to the statement.

Cover image: Tablets are pictured on the production line of Bristol Myers Squibb's pharmaceutical plant of French group UPSA (Union de pharmacologie scientifique appliquee) in Agen, southwestern France on March 29, 2018. 


Related Stories

Terms of Service & Privacy Policy

We have updated our privacy policy to comply with the latest laws and regulations. The updated policy explains the mechanism of how we collect and treat your personal data. You can learn more about the rights you have by reading our terms of service. Please read them carefully. By clicking AGREE, you indicate that you have read and agreed to our privacy policies

Agree and continue